drugset
drugset / Trial / NCT03933865

Acute Pain Management in Patients on Opioid Replacement Therapy

NCT03933865 ↗

Phase 1 Terminated 1 enrolled University of California, San Francisco
NaSingle-groupOpen-labelBasic science

Summary

This is an outpatient randomized within subject placebo-controlled human laboratory investigation of analgesia (as assessed with quantitative sensory testing; QST) from ketamine alone and in combination with hydromorphone in buprenorphine maintained participants. The goals of this project are to characterize the analgesic, subjective, and physiologic effects of ketamine combined with hydromorphone in patients on buprenorphine maintenance for opioid use disorder.

Timeline

Start
2018-10-31
Primary completion
2022-02-24
Completion
2022-02-24

Drugs

EvaluationDrugModalityDoseRoute
Subject Hydromorphone Other / unclassified 8 mg Intramuscular
Subject Ketamine Small molecule 0.1 mg/kg Intramuscular
Subject Ketamine Small molecule 0.2 mg/kg Intramuscular
Subject Ketamine Small molecule 0.4 mg/kg Intramuscular

Indications

opiate dependence